February 21, 2002

Dramatic Growth in Bioengineered Skin Market, Will Soon Eclipse Cartilage Market

FOOTHILL RANCH, CA—Growth in the leading bioengineered tissue market segments and expected developments in creating new bioengineered organs are expected to create a $1 billion market by 2010, forecasts MedMarket Diligence in its February issue of MedMarkets. 

“The two current leading market segments in bioengineered tissue are skin and cartilage,” said Patrick J. Driscoll, publisher of MedMarkets and President of MedMarket Diligence.  “However,” he continued, “growth in the skin segment, which is expected to see rates upwards of 40% annually between now and 2010, will rapidly overtake cartilage within a few years.”

“The next big area of growth will occur in five or six years as we begin to see new products emerging for human organs – products such as engineered kidney, heart muscle and artery cells,” Driscoll said.  Also under development are engineered tissues to treat diabetes, Parkinson’s and Alzheimer’s diseases as well as replacement tissue for damaged neural, cardiac and hepatic tissues.  Driscoll notes that after years of investment, key market players are finally beginning to convert clinical advances into profitability.

The February issue of MedMarkets also contains a feature article detailing recent developments in critical care including recent efforts to create individual genetic profiles for each critical care patient, important advances in brain and cardiac output monitoring, and review of recently reported results on pulse reflectance oximetry.  The article covers developments from Metracor Technologies, Masimo, Imagyn Medical Technologies, Physiometrix,, Aspect Medical Systems, SonoSite and Pulsion Medical Systems. 

MedMarkets is a key monthly industry publication from MedMarket Diligence, LLC, that analyzes the market and clinical practice implications of developments in medical technology —medical devices, equipment and supplies as well as biomaterials, biotech, pharmaceutical, e-health and others.

MedMarket Diligence provides tactical decision-making solutions on medical technology to the medical products and investment industries.  In addition to MedMarkets, the company publishes dedicated market/technology reports, and is developing other information solutions.  For more information on MedMarkets or MedMarket Diligence, LLC, contact Patrick Driscoll at (949) 859-3401, e-mail, or visit the Web site at http://www.mediligence.com to view a sample issue in its entirety.

Contact: Patrick Driscoll, (949) 859-3401